BetterLife Pharma Inc (BETRF)

BetterLife Pharma Inc. is a Canadian biotechnology company focused on developing compounds for mental health and neurological conditions, with additional research aimed at interferon-based technologies that may help the immune system respond to viral infections. Its pipeline includes BETR-001, which is being developed for major depressive disorder, anxiety disorder, neuropathic pain, and other neuro-psychiatric and neurological conditions, as well as BETR-002, a candidate targeting anxiety-related disorders, including benzodiazepine dependency. The company is also advancing MM-001, a topical interferon-alpha 2b cream that has completed Phase II clinical trials for local intravaginal use in HPV-induced cervical intraepithelial neoplasia, and MM-003, an inhalation formulation that has completed Phase II trials for COVID-19 and other respiratory viral infections. BetterLife Pharma was incorporated in 2002, adopted its current name in December 2019, and is headquartered in Vancouver, Canada. Its common stock trades on OTC Markets under the symbol BETR.F.

Jump directly to the stock analysis sections supported by the latest available data.